MedTrace Logo

Sublingual Misoprostol in Decreasing Blood Loss Prior to Myomectomy

NCT02709564 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-05-07

No results posted yet for this study

Summary

The aim of the study is to compare the effectiveness of sublingual administered prostaglandin E1 synthetic analogue (misoprostol) 400 microgram versus placebo before myomectomy to decrease blood loss during and after the operation.

Conditions

  • Blood Loss in Myomectomy

Interventions

DRUG

Misoprostol 400 sublingual

patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery

DRUG

placebo 400 sublingual

patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-12-31
Completion
2020-02-29

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02709564 on ClinicalTrials.gov